Advertisement

Hormones and Cancer

, Volume 10, Issue 4–6, pp 145–149 | Cite as

Assessing the Effect of Vitamin D Replacement on Basal Cell Carcinoma Occurrence and Recurrence Rates in Patients with Vitamin D Deficiency

  • Bilsev Ince
  • Mehmet Emin Cem YildirimEmail author
  • Mehmet Dadaci
Original Paper
  • 63 Downloads

Abstract

The study aimed to determine whether 25-OH vitamin D3 deficiency is present in patients with diagnosed BCC, and the effect of vitamin D replacement on the rates of BCC recurrence in patients with 25-OH vitamin D3 deficiency. In this prospective study, between 2012 and 2017, in the first stage, 25-OH vitamin D3 levels of all patients diagnosed with BCC between 2012 and 2013 were evaluated. In the second stage between 2014 and 2015, we evaluated the 25-OH vitamin D3 level of patients who had 25-OH vitamin D3 level < 25 ng/mL. All the patients included in the second stage had BCC recurrence. In the third stage, the patients who were diagnosed 25-OH vitamin D3 deficiency with BCC, between 2015 and 2017, were studied. The mean 25-OH vitamin D3 level of the patients in the second stage was 10.12 ng/mL. Recurrence was observed in 9.64% of the patients in the second stage. The mean level of serum 25-OH vitamin D3 in the third stage was 40.1 ng/mL, and 3.49% of these patients presented with recurrence. In all the patients as the initial diagnosis and following the 25-OH vitamin D3 level in all the patients with BCC recurrence, maintaining 25-OH vitamin D3 levels above 25 ng/mL can significantly reduce the recurrence rate.

Keywords

Basal cell carcinoma Vitamin D Skin cancers Vitamin D deficiency 

Notes

Acknowledgments

The authors thank Mehmet Uyar, MD, for his statistical analysis support.

Author Contributions

Study conception and design: Ince. Acquisition of data: Ince, Yildirim. Analysis and interpretation of data: Ince, Dadaci

Compliance with Ethical Standards

Disclaimer

The research was not sponsored by an outside organization. We (all of the authors) have agreed to allow full access to the primary data and to allow the journal to review the data if requested.

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Review Committee Statement

This study conformed to the Helsinki Declaration.

References

  1. 1.
    Goto M, Kai Y, Arakawa S et al (2012) Analysis of 256 cases of basal cell carcinoma after either one-step or two-step surgery in a Japanese institution. J Dermatol 39(1):68–71CrossRefGoogle Scholar
  2. 2.
    Tosetti F, Ferrari N, De Flora S et al (2002) Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16(1):2–14CrossRefGoogle Scholar
  3. 3.
    Ince B, Sakarya ME, Dadaci M (2018) An assessment of the effects of serum vitamin d levels on snoring in patients who have undergone septorhinoplasty. Turk J Plast Surg 26(2):50–55CrossRefGoogle Scholar
  4. 4.
    Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19(2):84–88CrossRefGoogle Scholar
  5. 5.
    Makarova A, Wang G, Dolorito JA, KC S, Libove E, Epstein EH Jr (2017) Vitamin D3 produced by skin exposure to UVR inhibits murine basal cell carcinoma carcinogenesis. J Invest Dermatol 137(12):2613–2619CrossRefGoogle Scholar
  6. 6.
    Tang JY, Parimi N, Wu A et al (2010) Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 21:387–391CrossRefGoogle Scholar
  7. 7.
    Park MS, Li T, Wu S et al (2016) Vitamin D intake and risk of skin cancer in US women and men. PLoS One 11(8):e0160308CrossRefGoogle Scholar
  8. 8.
    Altmeyer P, Hoffmann K, Stücker M (eds) (1997) Skin cancer and UV radiation. Springer, BerlinGoogle Scholar
  9. 9.
    Webb AR (2006) Who, what, where and when- influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 92(1):17–25CrossRefGoogle Scholar
  10. 10.
    DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80(6 Suppl):1689S–1696SCrossRefGoogle Scholar
  11. 11.
    Bikle DD, Nemanic MK, Gee E, Elias P (1986) 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kynetic and regulation. J Clin Invest 78(2):557–566CrossRefGoogle Scholar
  12. 12.
    Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiol Rev 78(4):1193–1231CrossRefGoogle Scholar
  13. 13.
    Walters MR (1992) Newly identified actions of the vitamin D endocrine system. Endocr Rev 13(4):719–764PubMedGoogle Scholar
  14. 14.
    Schuster I (2011) Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814(1):186–199CrossRefGoogle Scholar
  15. 15.
    Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41CrossRefGoogle Scholar
  16. 16.
    Deeb KK, Trump DL, Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7(9):684–700CrossRefGoogle Scholar
  17. 17.
    Gallagher RP, Hill GB, Bajdik CD et al (1995) Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 131(2):157–163CrossRefGoogle Scholar
  18. 18.
    Strickland PT, Vitasa BC, West SK, Rosenthal FS, Emmett EA, Taylor HR (1989) Quantitative carcinogenesis in man: solar ultraviolet B dose dependence of skin cancer in Maryland watermen. J Natl Cancer Inst 81(24):1910–1913CrossRefGoogle Scholar
  19. 19.
    Holick MF, Chen TC, Lu Z, Sauter E (2007) Vitamin D and skin physiology: a D-lightful story. J Bone Miner Res 22(Suppl 2):V28–V33CrossRefGoogle Scholar
  20. 20.
    Ince B, Uyar I, Dadaci M (2019) Effect of Vitamin D deficiency on hypertrophic scarring. Dermatol Surg 45(2):274–279CrossRefGoogle Scholar
  21. 21.
    Grant WB (2010) Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 101(2):130–136CrossRefGoogle Scholar
  22. 22.
    Baeke F, van Etten E, Gysemans C et al (2008) Vitamin D signaling in immune-mediated disorders: evolving insights and therapeutic opportunities. Mol Asp Med 29(6):376–387CrossRefGoogle Scholar
  23. 23.
    Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85(6):1586–1591CrossRefGoogle Scholar
  24. 24.
    Godar DE, Landry RJ, Lucas AD (2009) Increased UVA exposures and decreased cutaneous Vitamin D(3) levels may be responsible for the increasing incidence of melanoma. Med Hypotheses 72(4):434–443CrossRefGoogle Scholar
  25. 25.
    Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zügel U, Roman J (2010) Vitamin D inhibition of pro-fibrotic effects of transforming growth factor beta1 in lung fibroblasts and epithelial cells. J Steroid Biochem Mol Biol 118(3):142–150CrossRefGoogle Scholar
  26. 26.
    Shannan B, Seifert M, Boothman DA, Tilgen W, Reichrath J (2007) Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)2D3 in prostate cancer cells in vitro. J Steroid Biochem Mol Biol 103(3-5):721–725CrossRefGoogle Scholar
  27. 27.
    Perez-Lopez FR, Chedraui P, Haya J (2009) Review article: vitamin D acquisition and breast cancer risk. Reprod Sci 16(1):7–19CrossRefGoogle Scholar
  28. 28.
    Ince B, Yildirim MEC, Ismayilzade M, Dadaci M (2018) Vitamin D and systemic effects of vitamin D deficiency. Selcuk Med J 2(34):84–89Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Plastic & Reconstructive and Aesthetic Surgery, Meram Faculty of MedicineNecmettin Erbakan UniversityKonyaTurkey

Personalised recommendations